Sign In
Buy NBIX
$165.11
+10.27 (+6.63%)
At Close: Jun 03, 2026
Sarepta, Vertex, Neurocrine: There's Deep Value In These Beaten Down Healthcare Stocks
10:00am, Thursday, 01'st Jul 2021
Our theme of Out Of Favor Health Care Stocks includes healthcare and pharma names that are seeing a disconnect between their financial performance and stock price returns. Specifically, the theme filt
BofA Securities Makes Big Summer Changes to US 1 List of Top Stock Picks
07:09am, Wednesday, 30'th Jun 2021
With the second quarter of 2021 all but over and the latter half of 2021 right around the corner, many of the top companies we follow on Wall Street are making some changes to their lists of high-conv
Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment
10:27am, Wednesday, 02'nd Jun 2021
Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment.
Neurocrine Biosciences to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
04:01pm, Tuesday, 01'st Jun 2021
SAN DIEGO, June 1, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference at 1:20 p.m. Eastern Time on Tuesday, Ju
Neurocrine Biosciences: Pandemic Pressures And Few Pipeline Catalysts Continue To Weigh On NBIX
09:25am, Wednesday, 26'th May 2021
Neurocrine once again posted disappointing Ingrezza sales, and while the post-pandemic reopening should help, it likely won't be an immediate recovery. Management is advancing a broad pipeline of high
Neurocrine Biosciences to Present at the 2021 RBC Global Healthcare Conference
04:01pm, Tuesday, 11'th May 2021
SAN DIEGO, May 11, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 2021 RBC Capital Markets Healthcare Conference at 10:55 a.m. Eastern Time on Tuesday May 18, 20
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q1 2021 Results - Earnings Call Transcript
09:40pm, Wednesday, 05'th May 2021
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q1 2021 Results - Earnings Call Transcript
Neurocrine Biosciences (NBIX) Q1 Earnings and Revenues Miss Estimates
06:25pm, Wednesday, 05'th May 2021
Neurocrine (NBIX) delivered earnings and revenue surprises of -29.79% and -4.52%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine Biosciences Reports First Quarter 2021 Financial Results
04:01pm, Wednesday, 05'th May 2021
SAN DIEGO, May 5, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its financial results for the first quarter ended March 31, 2021 and provided revised full-year 2021
Neurocrine Biosciences to Present at the Bank of America 2021 Healthcare Conference
04:01pm, Tuesday, 04'th May 2021
SAN DIEGO, May 4, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Bank of America 2021 Healthcare Conference at 11:00 a.m. Eastern Time on Tuesday May 11, 2021.
Neurocrine Biosciences Supports Mental Health Month and Tardive Dyskinesia Awareness Week
08:30am, Monday, 03'rd May 2021
SAN DIEGO, May 3, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced its support of Mental Health Month and commitment to raising awareness of and supporting people livi
Neurocrine Biosciences Announces Appointment of Johanna Mercier to Board of Directors
09:00am, Friday, 16'th Apr 2021
SAN DIEGO, April 16, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Johanna Mercier to its Board of Directors. Ms. Mercier is the Chief Commercial
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2021 Financial Results
04:01pm, Wednesday, 14'th Apr 2021
SAN DIEGO, April 14, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report first quarter 2021 financial results after the Nasdaq market closes on Wednesd
Neurocrine Biosciences to Present Data from its Neurology Portfolio at the American Academy of Neurology's 73rd 2021 Virtual Meeting
04:01pm, Thursday, 08'th Apr 2021
SAN DIEGO, April 8, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it will present data from its movement disorders and epilepsy programs at the American Academ
Strength Seen in Neurocrine (NBIX): Can Its 11.1% Jump Turn into More Strength?
10:36am, Friday, 26'th Mar 2021
Neurocrine (NBIX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the
